{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:25:20Z","timestamp":1772472320493,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated the effect of statin intensity on the development of new onset diabetes mellitus (NODM) in Korean patients after percutaneous coronary intervention (PCI). A total of 1013 consecutive patients without diabetes mellitus were retrospectively analyzed. All study patients received high- or moderate-intensity statin (high-intensity statin; 321 [31.7%], moderate-intensity statin; 692 [68.3%]). The primary endpoint was development of NODM, and the secondary one was the composite of cardiac death, non-fatal myocardial infarction, and any revascularization. In 264 pairs (528 patients) of propensity score-matched patient, NODM developed in 34 patients (6.4%) and composite cardiac events occurred in 73 patients (13.8%) during a median follow-up of 36.7\u00a0months. The incidence rate of NODM was significantly higher in patients with high-intensity statin than with moderate-intensity statin (8.3% vs. 4.5%, log-rank P\u2009=\u20090.026). The incidence rate of composite events was not significantly different between the two groups (12.5% vs.15.2%, log-rank P\u2009=\u20090.495). The use of high-intensity statins was associated with NODM after adjustment for multiple risk factors (adjusted hazard ratio, 2.18, 95% confidence interval 1.10\u20124.51, P\u2009=\u20090.025). High-intensity statin therapy is associated with a higher incidence of NODM, but not with better cardiovascular outcomes, in Korean patients undergoing PCI. A new cholesterol lowering intensity-based approach rather than stain intensity-based approach to the high-risk patients without diabetes mellitus may be helpful in maximal treatment effect without safety concern of NODM in Asian patients.<\/jats:p>","DOI":"10.1038\/s41598-023-42277-w","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T18:02:20Z","timestamp":1695664940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New onset diabetes mellitus and cardiovascular outcomes according to statin intensity in patients after drug-eluting stent implantation in Asian patients"],"prefix":"10.1038","volume":"13","author":[{"given":"Jaehoon","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hack-Lyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-Hyun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Bing","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Heeg","family":"Zo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"42277_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000757","author":"SS Virani","year":"2020","unstructured":"Virani, S. S. et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation https:\/\/doi.org\/10.1161\/CIR.0000000000000757 (2020).","journal-title":"Circulation"},{"key":"42277_CR2","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation 139, e1082\u2013e1143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625 (2019).","journal-title":"Circulation"},{"key":"42277_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455 (2020).","journal-title":"Eur. Heart J."},{"key":"42277_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJM198807073190105","volume":"319","author":"SM Grundy","year":"1988","unstructured":"Grundy, S. M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319, 24\u201333. https:\/\/doi.org\/10.1056\/NEJM198807073190105 (1988).","journal-title":"N. Engl. J. Med."},{"key":"42277_CR5","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/j.jacc.2009.09.010","volume":"54","author":"CM Gibson","year":"2009","unstructured":"Gibson, C. M. et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22) substudy. J. Am. Coll. Cardiol. 54, 2290\u20132295. https:\/\/doi.org\/10.1016\/j.jacc.2009.09.010 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"42277_CR6","first-page":"1383","volume":"344","author":"Group, S. S. S. S","year":"1994","unstructured":"Group, S. S. S. S. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383\u20131389 (1994).","journal-title":"Lancet"},{"key":"42277_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1185\/030079902125000787","volume":"18","author":"VG Athyros","year":"2002","unstructured":"Athyros, V. G. et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u201cusual\u201d care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr. Med. Res. Opin. 18, 220\u2013228 (2002).","journal-title":"Curr. Med. Res. Opin."},{"key":"42277_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001\u20131009. https:\/\/doi.org\/10.1056\/NEJM199610033351401 (1996).","journal-title":"N. Engl. J. Med."},{"key":"42277_CR9","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz, G. G. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 285, 1711\u20131718 (2001).","journal-title":"JAMA"},{"key":"42277_CR10","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670\u20131681. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5 (2010).","journal-title":"Lancet"},{"key":"42277_CR11","doi-asserted-by":"publisher","first-page":"f2610","DOI":"10.1136\/bmj.f2610","volume":"346","author":"AA Carter","year":"2013","unstructured":"Carter, A. A. et al. Risk of incident diabetes among patients treated with statins: Population based study. BMJ 346, f2610. https:\/\/doi.org\/10.1136\/bmj.f2610 (2013).","journal-title":"BMJ"},{"key":"42277_CR12","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss, D. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 305, 2556\u20132564. https:\/\/doi.org\/10.1001\/jama.2011.860 (2011).","journal-title":"JAMA"},{"key":"42277_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P. & Glynn, R. J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 380, 565\u2013571. https:\/\/doi.org\/10.1016\/S0140-6736(12)61190-8 (2012).","journal-title":"Lancet"},{"key":"42277_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar, N. et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 375, 735\u2013742. https:\/\/doi.org\/10.1016\/S0140-6736(09)61965-6 (2010).","journal-title":"Lancet"},{"key":"42277_CR15","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","volume":"376","author":"Study of the Effectiveness of Additional Reductions in C","year":"2010","unstructured":"Study of the Effectiveness of Additional Reductions in C et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial. Lancet 376, 1658\u20131669. https:\/\/doi.org\/10.1016\/S0140-6736(10)60310-8 (2010).","journal-title":"Lancet"},{"key":"42277_CR16","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","volume":"57","author":"DD Waters","year":"2011","unstructured":"Waters, D. D. et al. Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 57, 1535\u20131545. https:\/\/doi.org\/10.1016\/j.jacc.2010.10.047 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"42277_CR17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","volume":"34","author":"Group, H. T. C","year":"2013","unstructured":"Group, H. T. C. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34, 1279\u20131291. https:\/\/doi.org\/10.1093\/eurheartj\/eht055 (2013).","journal-title":"Eur. Heart J."},{"key":"42277_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","volume":"99","author":"JK Liao","year":"2007","unstructured":"Liao, J. K. Safety and efficacy of statins in Asians. Am. J. Cardiol. 99, 410\u2013414. https:\/\/doi.org\/10.1016\/j.amjcard.2006.08.051 (2007).","journal-title":"Am. J. Cardiol."},{"key":"42277_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1253\/circj.CJ-17-0811","volume":"82","author":"SP Nagar","year":"2018","unstructured":"Nagar, S. P. et al. Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ. J. 82, 1008\u20131016. https:\/\/doi.org\/10.1253\/circj.CJ-17-0811 (2018).","journal-title":"Circ. J."},{"key":"42277_CR20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever, P. S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361, 1149\u20131158. https:\/\/doi.org\/10.1016\/S0140-6736(03)12948-0 (2003).","journal-title":"Lancet"},{"key":"42277_CR21","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/s0140-6736(03)13636-7","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins, R. et al. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361, 2005\u20132016. https:\/\/doi.org\/10.1016\/s0140-6736(03)13636-7 (2003).","journal-title":"Lancet"},{"key":"42277_CR22","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/s0140-6736(02)11600-x","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd, J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360, 1623\u20131630. https:\/\/doi.org\/10.1016\/s0140-6736(02)11600-x (2002).","journal-title":"Lancet"},{"issue":"2541\u20132619","key":"42277_CR23","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"TF Authors","year":"2014","unstructured":"Authors, T. F. et al. ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35(2541\u20132619), 2014. https:\/\/doi.org\/10.1093\/eurheartj\/ehu278 (2014).","journal-title":"Eur. Heart J."},{"key":"42277_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jacc.2011.12.001","volume":"59","author":"MR Patel","year":"2012","unstructured":"Patel, M. R., Dehmer, G. J., Hirshfeld, J. W., Smith, P. K. & Spertus, J. A. ACCF\/SCAI\/STS\/AATS\/AHA\/ASNC\/HFSA\/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J. Am. Coll. Cardiol. 59, 857\u2013881. https:\/\/doi.org\/10.1016\/j.jacc.2011.12.001 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"42277_CR25","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195\u20132207. https:\/\/doi.org\/10.1056\/NEJMoa0807646 (2008).","journal-title":"N. Engl. J. Med."},{"key":"42277_CR26","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen, T. R. et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 294, 2437\u20132445. https:\/\/doi.org\/10.1001\/jama.294.19.2437 (2005).","journal-title":"JAMA"},{"key":"42277_CR27","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495\u20131504. https:\/\/doi.org\/10.1056\/NEJMoa040583 (2004).","journal-title":"N. Engl. J. Med."},{"key":"42277_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","volume":"78","author":"E Lee","year":"2005","unstructured":"Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330\u2013341. https:\/\/doi.org\/10.1016\/j.clpt.2005.06.013 (2005).","journal-title":"Clin. Pharmacol. Ther."},{"key":"42277_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5551\/jat.10.329","volume":"10","author":"Y Saito","year":"2003","unstructured":"Saito, Y., Goto, Y., Dane, A., Strutt, K. & Raza, A. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J. Atheroscler. Thromb. 10, 329\u2013336. https:\/\/doi.org\/10.5551\/jat.10.329 (2003).","journal-title":"J. Atheroscler. Thromb."},{"key":"42277_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s0002-9149(02)02994-6","volume":"91","author":"DW Schneck","year":"2003","unstructured":"Schneck, D. W. et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol. 91, 33\u201341. https:\/\/doi.org\/10.1016\/s0002-9149(02)02994-6 (2003).","journal-title":"Am. J. Cardiol."},{"key":"42277_CR31","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ahj.2004.01.020","volume":"148","author":"GG Schwartz","year":"2004","unstructured":"Schwartz, G. G. et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: A randomized, controlled trial. Am. Heart J. 148, e4. https:\/\/doi.org\/10.1016\/j.ahj.2004.01.020 (2004).","journal-title":"Am. Heart J."},{"key":"42277_CR32","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","volume":"368","author":"H Nakamura","year":"2006","unstructured":"Nakamura, H. et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 368, 1155\u20131163. https:\/\/doi.org\/10.1016\/S0140-6736(06)69472-5 (2006).","journal-title":"Lancet"},{"key":"42277_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0002-9343(91)90053-z","volume":"91","author":"CA Dujovne","year":"1991","unstructured":"Dujovne, C. A. et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am. J. Med. 91, 25\u201330. https:\/\/doi.org\/10.1016\/0002-9343(91)90053-z (1991).","journal-title":"Am. J. Med."},{"key":"42277_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative, G","year":"2002","unstructured":"Heart Protection Study Collaborative, G. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360, 7\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(02)09327-3 (2002).","journal-title":"Lancet"},{"key":"42277_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian, M. et al. clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014. JAMA 316, 602\u2013610. https:\/\/doi.org\/10.1001\/jama.2016.10924 (2016).","journal-title":"JAMA"},{"key":"42277_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2337\/dc16-2641","volume":"40","author":"SD Solomon","year":"2017","unstructured":"Solomon, S. D. et al. Diabetic retinopathy: A position statement by the American Diabetes Association. Diabetes Care 40, 412\u2013418. https:\/\/doi.org\/10.2337\/dc16-2641 (2017).","journal-title":"Diabetes Care"},{"key":"42277_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi, F. et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 376, 419\u2013430. https:\/\/doi.org\/10.1016\/S0140-6736(10)60576-4 (2010).","journal-title":"Lancet"},{"key":"42277_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","volume":"40","author":"R Pop-Busui","year":"2017","unstructured":"Pop-Busui, R. et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care 40, 136\u2013154. https:\/\/doi.org\/10.2337\/dc16-2042 (2017).","journal-title":"Diabetes Care"},{"key":"42277_CR39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","volume":"14","author":"GJ Biessels","year":"2018","unstructured":"Biessels, G. J. & Despa, F. Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications. Nat. Rev. Endocrinol. 14, 591\u2013604. https:\/\/doi.org\/10.1038\/s41574-018-0048-7 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"42277_CR40","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1161\/ATVBAHA.121.316159","volume":"41","author":"F Abbasi","year":"2021","unstructured":"Abbasi, F. et al. statins are associated with increased insulin resistance and secretion. Arterioscler. Thromb. Vasc. Biol. 41, 2786\u20132797. https:\/\/doi.org\/10.1161\/ATVBAHA.121.316159 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"42277_CR41","doi-asserted-by":"publisher","first-page":"g3244","DOI":"10.1136\/bmj.g3244","volume":"348","author":"CR Dormuth","year":"2014","unstructured":"Dormuth, C. R. et al. Higher potency statins and the risk of new diabetes: Multicentre, observational study of administrative databases. BMJ 348, g3244. https:\/\/doi.org\/10.1136\/bmj.g3244 (2014).","journal-title":"BMJ"},{"key":"42277_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3949\/ccjm.83gr.16001","volume":"83","author":"MS Sabatine","year":"2016","unstructured":"Sabatine, M. S. Advances in the treatment of dyslipidemia. Cleve Clin. J. Med. 83, 181\u2013186. https:\/\/doi.org\/10.3949\/ccjm.83gr.16001 (2016).","journal-title":"Cleve Clin. J. Med."},{"key":"42277_CR43","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387\u20132397. https:\/\/doi.org\/10.1056\/NEJMoa1410489 (2015).","journal-title":"N. Engl. J. Med."},{"key":"42277_CR44","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","volume":"37","author":"HM Colhoun","year":"2016","unstructured":"Colhoun, H. M. et al. No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur. Heart J. 37, 2981\u20132989. https:\/\/doi.org\/10.1093\/eurheartj\/ehw292 (2016).","journal-title":"Eur. Heart J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42277-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T06:10:34Z","timestamp":1700374234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42277-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42277"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-42277-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16061"}}